Abiopharma

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Philips Future Health Index cardiology snapshot reveals trust gap in AI for care

New Form 8-K - BIO-RAD LABORATORIES, INC. Filed: 2025-08-26 AccNo: 0000012208-25-000054 Size: 2 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Envoy Medical, Inc. Filed: 2025-08-26 AccNo: 0001213900-25-080530 Size: 296 KB Item 1.02: Termination of a Material Definitive Agreement Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

Westlake anuncia la adquisición de ACI Compounding Solutions Business

Health Catalyst Announces Upfront: Market Insights on Salesforce AppExchange

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

DexCom, Inc. - Dexcom Announces Upcoming Conference Presentations

National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced

Odyssey Health, Inc. to Advance Development of its Save A Life Choking Rescue Device

Dexcom Announces Upcoming Conference Presentations

CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy

Director WEHRWEIN SVEN 🟡 adjusted position in 5.0K shares (1 derivative) of AtriCure, Inc. (ATRC) at $37.00 Transaction Date: Aug 22, 2025 | Filing ID: 000005

New Form SC 14D9/A - DURECT CORP Filed: 2025-08-26 AccNo: 0001193125-25-188167 Size: 22 KB